Abstract
A pooled data analysis of two double-blind studies encompassing 1137 episodes of community-acquired pneumonia in hospitalised adults, of which 560 were treated with sparfloxacin and 577 were randomised to comparator antibacterial agents (amoxycillin/clavulanic acid, erythromycin or amoxycillin administered at reference dosages), was performed. The global efficacy rate at the end of treatment in evaluable patients treated with sparfloxacin was 88.3% compared with 84.1% in those who received comparator antibacterial agents. This analysis verified the efficacy of this new aminofluoroquinolone, given orally once daily, in the treatment of community acquired pneumonia. The overall outcome favoured sparfloxacin for use in the empirical treatment of community-acquired pneumonia.
Publication types
-
Clinical Trial
-
Comparative Study
-
Multicenter Study
-
Randomized Controlled Trial
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Adult
-
Amoxicillin / therapeutic use
-
Amoxicillin-Potassium Clavulanate Combination
-
Anti-Bacterial Agents / therapeutic use
-
Anti-Infective Agents / therapeutic use*
-
Clavulanic Acids / therapeutic use
-
Community-Acquired Infections / drug therapy*
-
Community-Acquired Infections / microbiology
-
Double-Blind Method
-
Drug Therapy, Combination / therapeutic use
-
Erythromycin / therapeutic use
-
Fluoroquinolones*
-
Humans
-
Microbial Sensitivity Tests
-
Penicillins / therapeutic use
-
Pneumonia, Bacterial / drug therapy*
-
Pneumonia, Bacterial / microbiology
-
Quinolones / therapeutic use*
-
Streptococcus pneumoniae / drug effects
Substances
-
Anti-Bacterial Agents
-
Anti-Infective Agents
-
Clavulanic Acids
-
Fluoroquinolones
-
Penicillins
-
Quinolones
-
Erythromycin
-
Amoxicillin-Potassium Clavulanate Combination
-
Amoxicillin
-
sparfloxacin